Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 50,200 shares, a decline of 28.7% from the November 30th total of 70,400 shares. Based on an average daily volume of 273,900 shares, the days-to-cover ratio is presently 0.2 days. Approximately 9.4% of the shares of the stock are short sold.

Bone Biologics Price Performance

Shares of NASDAQ BBLG remained flat at $0.95 on Friday. 203,428 shares of the company’s stock traded hands, compared to its average volume of 1,372,615. The company has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $1.46. Bone Biologics has a 12 month low of $0.80 and a 12 month high of $10.56.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.